A Registry Study on Xiyanping(a Chinese Medicine Injection) Used in Fifty Hospitals
NCT ID: NCT01612572
Last Updated: 2012-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
20000 participants
OBSERVATIONAL
2012-01-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It was funded by China major scientific and technological specialized project for 'significant new formulation of new drugs'.
Xiyanping is kind of Chinese Medicine injection used for treating viral pneumonia 、bronchitis、amygdalitis、infantile diarrhea、bacillary dysentery 、virus hepatitis、and Children acute hot diseases in many Chinese hospitals.
The purpose of this study is to determine adverse drug events or adverse drug reaction in large sample size 20,000 patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Registry Study on Tanreqing（a Chinese Medicine Injection）Used in Hospitals in China
NCT01824732
Traditional Chinese Medicine for Severe COVID-19
NCT04323332
Safety Study of Shenfu (a Chinese Medicine Injection) Used in Hospitals in China
NCT01612533
Safety Study of DanshenDuofensuanyan(a Chinese Medicine Injection)Used in Hospitals in China
NCT01814566
A Registry Study on Reduning（a Chinese Medicine Injection）Used in Hospitals in China
NCT01824719
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In order to ensure the safety of public drug use and lower drug-induced risks, a registry study for Xiyanping injection safety surveillance with 20000 patients will be conducted from Jan.2012 to Dec.2015.
Eligibility criteria Patients who will use Xiyanping injection in selected hospitals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China Academy of Chinese Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yanming Xie
Deputy Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yan M Xie, BA
Role: PRINCIPAL_INVESTIGATOR
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RSCMI- Ⅲ
Identifier Type: -
Identifier Source: secondary_id
RSCMI-Ⅲ
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.